Lndoleamine 2, 3-dioxygenase activity during fulvestrant therapy for aromatase inhibitor resistant metastatic breast cancer

Kenichi Sakurai; Shigeru Fujisaki; Hitomi Kubota; Yukiko Hara; Shuhei Suzuki; Keita Adachi; Ryouichi Tomita; Katsuhisa Enomoto; Tomohiro Hirano; Reina Saga; Makoto Makishima

Lndoleamine 2, 3-dioxygenase activity during fulvestrant therapy for aromatase inhibitor resistant metastatic breast cancer

Kenichi Sakurai, Shigeru Fujisaki, Hitomi Kubota, Yukiko Hara, Shuhei Suzuki, Keita Adachi, Ryouichi Tomita, Katsuhisa Enomoto, Tomohiro Hirano, Reina Saga, Makoto Makishima

School of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) for breast cancer patients between different clinical stages and patient ages. IDO activity was measured by the tryptophan (Trp)Aynurenine (Kyn) ratio. Trp and Kyn levels were measured using high performance liquid chromatography (HPLC). Serum Trp/Kyn levels in Stage IV breast cancer patients were lower than in patients at other stages. Serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. Within the same clinical stage, serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. These results suggest that the immunological profile of breast cancer patients over the age of 70 years may be immunosuppressive compared to breast cancer patients under the age of 69 years.

Original language	English
Pages (from-to)	886-888
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	44
Issue number	10
Publication status	Published - Oct 2017

Keywords

Breast cancer
Fulvestrant
Indoleamine 2 3-dioxygenase (IDO)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{697cd24b51184d009e3c392cd4b924e9,

title = "Lndoleamine 2, 3-dioxygenase activity during fulvestrant therapy for aromatase inhibitor resistant metastatic breast cancer",

abstract = "We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) for breast cancer patients between different clinical stages and patient ages. IDO activity was measured by the tryptophan (Trp)Aynurenine (Kyn) ratio. Trp and Kyn levels were measured using high performance liquid chromatography (HPLC). Serum Trp/Kyn levels in Stage IV breast cancer patients were lower than in patients at other stages. Serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. Within the same clinical stage, serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. These results suggest that the immunological profile of breast cancer patients over the age of 70 years may be immunosuppressive compared to breast cancer patients under the age of 69 years.",

keywords = "Breast cancer, Fulvestrant, Indoleamine 2 3-dioxygenase (IDO)",

author = "Kenichi Sakurai and Shigeru Fujisaki and Hitomi Kubota and Yukiko Hara and Shuhei Suzuki and Keita Adachi and Ryouichi Tomita and Katsuhisa Enomoto and Tomohiro Hirano and Reina Saga and Makoto Makishima",

year = "2017",

month = oct,

language = "English",

volume = "44",

pages = "886--888",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "10",

}

TY - JOUR

T1 - Lndoleamine 2, 3-dioxygenase activity during fulvestrant therapy for aromatase inhibitor resistant metastatic breast cancer

AU - Sakurai, Kenichi

AU - Fujisaki, Shigeru

AU - Kubota, Hitomi

AU - Hara, Yukiko

AU - Suzuki, Shuhei

AU - Adachi, Keita

AU - Tomita, Ryouichi

AU - Enomoto, Katsuhisa

AU - Hirano, Tomohiro

AU - Saga, Reina

AU - Makishima, Makoto

PY - 2017/10

Y1 - 2017/10

N2 - We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) for breast cancer patients between different clinical stages and patient ages. IDO activity was measured by the tryptophan (Trp)Aynurenine (Kyn) ratio. Trp and Kyn levels were measured using high performance liquid chromatography (HPLC). Serum Trp/Kyn levels in Stage IV breast cancer patients were lower than in patients at other stages. Serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. Within the same clinical stage, serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. These results suggest that the immunological profile of breast cancer patients over the age of 70 years may be immunosuppressive compared to breast cancer patients under the age of 69 years.

AB - We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) for breast cancer patients between different clinical stages and patient ages. IDO activity was measured by the tryptophan (Trp)Aynurenine (Kyn) ratio. Trp and Kyn levels were measured using high performance liquid chromatography (HPLC). Serum Trp/Kyn levels in Stage IV breast cancer patients were lower than in patients at other stages. Serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. Within the same clinical stage, serum Trp/Kyn levels of breast cancer patients over the age of 70 years were lower than in patients under the age of 69 years. These results suggest that the immunological profile of breast cancer patients over the age of 70 years may be immunosuppressive compared to breast cancer patients under the age of 69 years.

KW - Breast cancer

KW - Fulvestrant

KW - Indoleamine 2 3-dioxygenase (IDO)

UR - http://www.scopus.com/inward/record.url?scp=85040526173&partnerID=8YFLogxK

M3 - Review article

C2 - 29066685

AN - SCOPUS:85040526173

SN - 0385-0684

VL - 44

SP - 886

EP - 888

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 10

ER -

Lndoleamine 2, 3-dioxygenase activity during fulvestrant therapy for aromatase inhibitor resistant metastatic breast cancer

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this